Skip to main content

Soluble ST2: a valuable prognostic marker in heart failure


Natriuretic peptides have been at the forefront of biomarker use in heart disease and have been universally recommended as the ideal biomarker in the setting of heart failure. Soluble ST2 is one such biomarker which has found value as a prognostic marker and can be used individually or along with natriuretic peptides in order to prognosticate patients with heart failure. Leading cardiovascular organisations have recognised this biomarker, though its role as a diagnostic marker is yet to be determined. We aim to investigate the role of sST2 in heart failure in the existing literature.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. Villacorta H, Maisel AS (2016) Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol 106(2):145–152.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. Aleksova A, Paldino A, Beltrami AP et al (2019) Cardiac biomarkers in the emergency department: the role of soluble ST2 (sST2) in acute heart failure and acute coronary syndrome-there is meat on the bone. J Clin Med 8(2):270. Published 2019 Feb 22.

  3. Zhang T, Xu C, Zhao R, Cao Z (2021) Diagnostic value of sST2 in Cardiovascular diseases: a systematic review and meta-analysis. Front Cardiovasc Med 8:697837. Published 2021 Jul 23.

  4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group (2021) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 42(36):3599–3726. (Erratum in: Eur Heart J 2021 Oct 14 PMID: 34447992)

  5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129–2200. (Epub 2016 May 20 Erratum in: Eur Heart J 2016 Dec 30 PMID: 27206819)

  6. Jin XL, Huang N, Shang H et al (2018) Diagnosis of chronic heart failure by the soluble suppression of tumorigenicity 2 and N-terminal pro-brain natriuretic peptide. J Clin Lab Anal 32(3):e22295.

    CAS  Article  Google Scholar 

  7. Henry-Okafor Q, Collins SP, Jenkins CA et al (2012) Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes. Open Biomark J 2012(5):1–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdés M, Januzzi JL (2011) Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 13(7):718–725. (Epub 2011 May 6 PMID: 21551163)

    CAS  Article  PubMed  Google Scholar 

  9. Tang WH, Wu Y, Grodin JL, Hsu AP, Hernandez AF, Butler J, Metra M, Voors AA, Felker GM, Troughton RW, Mills RM, McMurray JJ, Armstrong PW, O’Connor CM, Starling RC (2016) Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure. JACC Heart Fail 4(1):68–77. (Epub 2015 Dec 2 PMID: 26656144)

    Article  PubMed  Google Scholar 

  10. Manzano-Fernández S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL (2011) Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 107(2):259–267.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Ky B, French B, McCloskey K et al (2011) High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4(2):180–187.

    Article  PubMed  Google Scholar 

  12. Emdin M, Aimo A, Vergaro G, Bayes-Genis A, Lupón J, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Gullestad L, Broch K, Ueland T, Nymo SH, Brunner-La Rocca HP, de Boer RA, Gaggin HK, Ripoli A, Passino C, Januzzi JL Jr (2018) sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol 72(19):2309–2320. (PMID: 30384887)

    CAS  Article  PubMed  Google Scholar 

  13. Bahuleyan CG, Alummoottil GK, Abdullakutty J et al (2018) Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - a multicenter study. Indian Heart J 70 Suppl 1(Suppl 1):S79-S84.

  14. Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, Yokoshiki H, Tsutsui H; JCARE-CARD Investigators (2012) Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 76(7):1662–9. (Epub 2012 Apr 6 PMID: 22481105)

  15. Sugano A, Seo Y, Ishizu T, Sai S, Yamamoto M, Hamada-Harimura Y, Machino-Ohtsuka T, Obara K, Nishi I, Aonuma K, Nogami A (2019) Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction. J Cardiol 73(4):326–332. (Epub 2018 Dec 20 PMID: 30580891)

    Article  PubMed  Google Scholar 

  16. Dalal JJ, Digrajkar A, Das B, Bansal M, Toomu A, Maisel AS (2018) ST2 elevation in heart failure, predictive of a high early mortality. Indian Heart J 70(6):822–827. (Epub 2018 Aug 31 PMID: 30580851 PMCID: PMC6306350)

  17. Geenen LW, Baggen VJM, van den Bosch AE, Eindhoven JA, Cuypers JAAE, Witsenburg M, Boersma E, Roos-Hesselink JW (2019) Prognostic value of soluble ST2 in adults with congenital heart disease. Heart 105(13):999–1006. (Epub 2019 Jan 30 PMID: 30700520 PMCID: PMC6582725)

  18. Lancellotti P, Dulgheru R, Magne J et al (2015) Elevated plasma soluble ST2 is associated with heart failure symptoms and outcome in aortic stenosis. PLoS One 10(9):e0138940. Published 2015 Sep 21.

  19. Cai A, Miyazawa A, Sunderland N et al (2021) ST2 in patients with severe aortic stenosis and heart failure. Cardiol J 28(1):129–135.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Jenkins WS, Roger VL, Jaffe AS et al (2017) Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am J Med 130(9):1112.e9-1112.e15.

    CAS  Article  Google Scholar 

  21. Kim HL, Lee JP, Wong N, Lim WH, Seo JB, Zo JH, Kim MA, Kim SH (2021) Prognostic value of serum soluble ST2 in stable coronary artery disease: a prospective observational study. Sci Rep 11(1):15203.;PMCID:PMC8313553

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Ma X, Yuan H, Luan HX, Shi YL, Zeng XL, Wang Y (2018) Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation. Clin Chim Acta 480:138–142. (Epub 2018 Feb 8 PMID: 29428199)

    CAS  Article  PubMed  Google Scholar 

  23. Bayes-Genis A, de Antonio M, Galán A, Sanz H, Urrutia A, Cabanes R, Cano L, González B, Díez C, Pascual T, Elosúa R, Lupón J (2012) Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 14(1):32–38. (PMID: 22179033)

    CAS  Article  PubMed  Google Scholar 

  24. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19):3121–3128. (Epub 2004 Nov 1 PMID: 15520318)

    CAS  Article  PubMed  Google Scholar 

  25. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136(6):e137–e161. (Epub 2017 Apr 28 PMID: 28455343)

    Article  PubMed  Google Scholar 

  26. Cui Y, Qi X, Huang A, Li J, Hou W, Liu K (2018) Differential and predictive value of galectin-3 and soluble suppression of tumorigenicity-2 (sST2) in heart failure with preserved ejection fraction. Med Sci Monit 24:5139–5146. Published 2018 Jul 24.

  27. Mueller T, Gegenhuber A, Leitner I, Poelz W, Haltmayer M, Dieplinger B (2016) Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure. Clin Chim Acta 1(463):158–164. (Epub 2016 Oct 29 PMID: 27983996)

    CAS  Article  Google Scholar 

  28. Dupuy AM, Curinier C, Kuster N et al (2016) Multi-marker strategy in heart failure: combination of ST2 and CRP predicts poor outcome. PLoS One 11(6):e0157159. Published 2016 Jun 16.

  29. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL Jr (2013) Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ Heart Fail 6(6):1206–1213. (Epub 2013 Oct 10 PMID: 24114865)

    CAS  Article  PubMed  Google Scholar 

  30. Lupón J, de Antonio M, Vila J et al (2014) Development of a novel heart failure risk tool: the Barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS One 9(1):e85466. Published 2014 Jan 15.

  31. Barcelona Bio-HF Risk calculator. Accessed 8 January 2022.

  32. Hur M, Kim H, Kim HJ, Yang HS, Magrini L, Marino R, Cardelli P, Di Somma S, GREAT Network (2015) Soluble ST2 has a prognostic role in patients with suspected sepsis. Ann Lab Med 35(6):570–7. (PMID: 26354344; PMCID: PMC4579100)

  33. Miller WL, Saenger AK, Grill DE, Slusser JP, Bayes-Genis A, Jaffe AS (2016) Prognostic value of serial measurements of soluble suppression of tumorigenicity 2 and galectin-3 in ambulatory patients with chronic heart failure. J Card Fail 22(4):249–255. (Epub 2015 Aug 14 PMID: 26277907)

    CAS  Article  PubMed  Google Scholar 

  34. Manzano-Fernández S, Januzzi JL, Pastor-Pérez FJ, Bonaque-González JC, Boronat-Garcia M, Pascual-Figal DA, Montalban-Larrea S, Navarro-Peñalver M, Andreu-Cayuelas JM, Valdés M (2012) Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 122(3):158–166. (Epub 2012 Jul 24 PMID: 22832599)

    CAS  Article  PubMed  Google Scholar 

  35. Savvoulidis P, Snider JV, Rawal S et al (2020) Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. Int J Cardiol 304:116–121.

    Article  PubMed  Google Scholar 

  36. Crnko S, Printezi MI, Jansen TPJ et al (2020) Prognostic biomarker soluble ST2 exhibits diurnal variation in chronic heart failure patients. ESC Heart Fail 7(3):1224–1233.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kim MS, Jeong TD, Han SB, Min WK, Kim JJ (2015) Role of soluble ST2 as a prognostic marker in patients with acute heart failure and renal insufficiency. J Korean Med Sci 30(5):569–575.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations



All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Sugeevan Savarimuthu, Pavan Goel, and Amer Harky. The first draft of the manuscript was written by Sugeevan Savarimuthu, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. All authors have read and approve of the data being presented in the manuscript.

Corresponding author

Correspondence to Sugeevan Savarimuthu.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This manuscript has not been submitted or published elsewhere.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Savarimuthu, S., Goel, P. & Harky, A. Soluble ST2: a valuable prognostic marker in heart failure. Heart Fail Rev (2022).

Download citation

  • Accepted:

  • Published:

  • DOI:


  • Heart failure
  • Soluble ST2
  • Natriuretic peptide
  • Biomarker